Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NYSE | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 23 | -1.19 Decreased by -11.21% | -0.33 Decreased by -789.72% |
| Apr 3, 23 | -0.38 Increased by +47.22% | -1.05 Increased by +60.77% |
| Mar 15, 23 | -0.75 Increased by 0.00% | -1.15 Increased by +30.25% |
| Nov 8, 22 | -0.93 Decreased by -165.71% | -1.01 Increased by +7.84% |
| Aug 8, 22 | -1.07 Decreased by -214.71% | -0.64 Decreased by -104.98% |
| May 4, 22 | -0.72 Decreased by -380.00% | -0.58 Decreased by -41.62% |
| Mar 2, 22 | -0.75 Decreased by -120.59% | -0.25 Decreased by -800.00% |
| Nov 3, 21 | -0.35 Increased by +70.59% | -0.44 Increased by +46.49% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -29.44 M Decreased by -402.90% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.02 M Increased by +48.84% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -7.52 M Decreased by -163.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -8.65 M Decreased by -242.47% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -5.85 M Decreased by -82.98% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -5.90 M Decreased by -246.34% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -2.85 M Decreased by -183.02% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -2.52 M Decreased by -9.31% | Decreased by N/A% Decreased by N/A% |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.